Auxological characteristics of pediatric patients with permanent or transient isolated growth hormone deficiency. Response to treatment and final height

Villafuerte, Beatriz; Barrio, Raquel; Martín-Frías, Maria; Alonso, Milagros; Roldán, Belén

doi:10.1016/j.endien.2018.11.015

Cited by 3 publications

(3 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Mean height SDS in our study (−4.02 for SGHD, −2.63 for PGHD, and − 3.56 for MPHD) is similar to what has been previously noticed by other Indian studies by Acharya et al ,[ 4 ] Khadilkar et al ,[ 15 ] and Gahlot et al [ 16 ] These findings are distinct as compared to developed countries as reported by Darendeliler et al ,[ 17 ] Villafuerte et al ,[ 18 ] Lo et al ,[ 14 ] and Nagel et al ,[ 19 ] who observed a higher height SDS among these patients, and Rohayem et al [ 20 ] who observed a lower height SDS (−4.1 SDS for MPHD) among these patients. Although these differences could be ascribed to ethnic variations, this could be due to the delayed presentation and lack of awareness regarding GHD in the study population.…”

Section: Discussionsupporting

confidence: 91%

Clinical and Biochemical Phenotype of Indian Children with Different Types of Idiopathic Growth Hormone Deficiency and their Association with Pituitary Height on MRI

Sharma

Mathur

Purwar

et al. 2021

Indian Journal of Endocrinology and Metabolism

View full text Add to dashboard Cite

Background and Objectives: Differentiation of growth hormone deficiency (GHD) into various types has been made based on peak stimulated growth hormone levels and other hormone axis involvement. The data regarding how this classification is associated with variation in clinical and biochemical phenotype and how these findings associate with pituitary morphology remains sparse, especially in the Indian population. Therefore, we aimed to ascertain the differences in the pattern of auxological, clinical features including pituitary hypoplasia, and endocrinological profile among patients with severe GHD, partial GHD, and MPHD in the Indian population and to evaluate the association of pituitary height with various clinical and hormonal parameters. Materials and Methods: We conducted a cross-sectional study in 100 patients with idiopathic GHD. Patients were grouped into severe GHD, partial GHD, and MPHD to observe the differences in clinical, biochemical, and MRI findings. The pituitary height findings were correlated clinical and biochemical presentation. Results: MPHD subjects had a significantly higher frequency of breech delivery, neonatal jaundice, neonatal hypoglycemia, and micropenis. A significant difference was observed in the chronological age, bone age retardation (CA-BA), height SDS, weight SDS, peak GH response, IGF-1, IGF-1 SDS, and prevalence of pituitary hypoplasia, pituitary height, and pituitary height SDS among these three groups. In the composite population of GHD, pituitary height SDS was correlated with peak GH, basal IGF-I SDS, and body height SDS. Conclusion: The clinical and biochemical phenotype differs significantly among the various types of GHD. Pituitary height correlates with these findings and is helpful in further assessment of these patients.

show abstract

Section: Discussionsupporting

confidence: 91%

Clinical and Biochemical Phenotype of Indian Children with Different Types of Idiopathic Growth Hormone Deficiency and their Association with Pituitary Height on MRI

Sharma

Mathur

Purwar

et al. 2021

Indian Journal of Endocrinology and Metabolism

View full text Add to dashboard Cite

show abstract

“…The most important finding of our study is that the median nFHt is similar to the THt, gaining 1.27 SDS as compared to Ht at diagnosis. In our cohort, the age at diagnosis was 11 years, consistent with most studies on the topic, which show that it ranges between 10 and 11 years [17][18][19][20], or even later [21]. Only a few papers report an age of 8 years in females and 9 years in males [22,23].…”

Section: Discussionsupporting

confidence: 88%

Isolated childhood growth hormone deficiency: a 30-year experience on final height and a new prediction model

Lonero

Giotta

Guerrini

et al. 2022

J Endocrinol Invest

View full text Add to dashboard Cite

Purpose We aimed to evaluate the near-final height (nFHt) in a large cohort of pediatricpatients with growth hormone deficiency (GHD) and to elaborate a new predictive method of nFHt. Methods We recruited GHD patients diagnosed between 1987 and 2014 and followed-up until nFHt. To predict the values of nFHt, each predictor was run in a univariable spline. ResultsWe enrolled 1051 patients. Pre-treatment height was −2.43 SDS, lower than parental height (THt) (−1.09 SDS, p < 0.001). The dose of recombinant human GH (rhGH) was 0.21mg/kg/week at start of treatment. nFHt was −1.08 SDS (height gain 1.27 SDS), higher than pre-treatment height (p < 0.001) and comparable to THt. 1.6% of the patients were shorter than −2 SDS from THt. The rhGH dose at nFHt was 0.19 mg/kg/week, lower than at the start (p < 0.001). The polynomial regression showed that nFHt was affected by gender, THt, age at puberty, height at puberty, age at the end of treatment (F = 325.37, p < 0.0001, R 2 87.2%). Conclusion This large national study shows that GHD children can reach their THt. The rhGH/kg/day dose significantly decreased from the start to the end of the treatment. Our model suggests the importance of a timely diagnosis, possibly before puberty, the beneficial effect of long-term treatment with rhGH, and the key-role of THt. Our prediction model has a very acceptable error compared to the majority of other published studies.

show abstract

“…Accordingly, there is disagreement as to whether patients with Growth Hormone Deficiency (GHD) respond better to GH than patients with Idiopathic Short Stature (ISS), with some of the difference likely being due to how strictly GHD is defined. In fact, patients with permanent GHD yield better results than those with transitory GHD, just as patients with multiple pituitary deficiencies show better results than those with isolated growth hormone deficiency [ 9 , 10 ].…”

Section: Introductionmentioning

confidence: 99%

Isolated Growth Hormone Deficiency and Idiopathic Short Stature: Comparative Efficiency after Growth Hormone Treatment up to Adult Height

Jiménez

Leiva-Gea

Ollero

et al. 2021

JCM

View full text Add to dashboard Cite

Introduction: Treatment with growth hormone (GH) is not approved for idiopathic short stature (ISS) in Europe. Objectives: To compare the growth of children treated with isolated GH deficiency (IGHD) vs. ISS-treated and untreated children. Methods: A retrospective descriptive study of patients treated in the last 14 years for IGHD (Group A), in comparison with ISS-treated (Group B) and untreated (Group C) subjects. Results: Group A had 67 males, who showed a height gain of 1.24 SD. Group B had 30 boys, who showed a height gain of 1.47 SD. Group C had 42 boys, who showed an improvement of 0.37 SD. The final heights were −1.52 SD, −1.31 SD, and −2.03 SD, respectively. Group A and C did not reach their target heights (with differences of 0.27 SD and 0.59 SD, respectively). Group B surpassed their target height by 0.29 SD. Conclusions: The final heights of the IGHD and treated ISS are similar. Treated groups were taller than untreated groups.

show abstract

Auxological characteristics of pediatric patients with permanent or transient isolated growth hormone deficiency. Response to treatment and final height

Cited by 3 publications

References 25 publications

Clinical and Biochemical Phenotype of Indian Children with Different Types of Idiopathic Growth Hormone Deficiency and their Association with Pituitary Height on MRI

Clinical and Biochemical Phenotype of Indian Children with Different Types of Idiopathic Growth Hormone Deficiency and their Association with Pituitary Height on MRI

Isolated childhood growth hormone deficiency: a 30-year experience on final height and a new prediction model

Isolated Growth Hormone Deficiency and Idiopathic Short Stature: Comparative Efficiency after Growth Hormone Treatment up to Adult Height

Contact Info

Product

Resources

About